NEW YORK (360Dx) – The broader markets weighed down the share prices of almost every diagnostic firm in December as the 360Dx Index slid nearly 12 percent compared to November. 

Of the 28 companies in the index, only one, Veracyte (+3 percent), saw a month-over-month improvement in its stock price last month.